Canada’s drug-pricing regulator brings rare allegation of excessive pricing against Horizon Pharma - (The Globe and Mail via NewsPoints Desk)

  • Canada's Patented Medicine Prices Review Board has accused Horizon Pharma of setting an excessive price for its rare disease drug Procysbi, The Globe and Mail reported.

  • The drug's cost of about $325 000 a year is 65-fold higher than that of Cystagon, an older containing the same active ingredient.

  • The regulator said Horizon should drastically lower the price of the drug and pay up to $3.15 million to Canada to account for "excess" revenue generated since the drug was approved by Health Canada in 2017.

  • "There is no reason why two products which contain the same medicinal ingredient and are indicated for the same condition in the same population should be priced differently," the board’' staff stated.

  • The case is expected to advance to a quasi-judicial public hearing.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.